fda and semaglutide compounding sets tirzepatide deadlines as shortage ends Legal Insights into Peptide and

The medication acts on corresponding receptors in the central nervous system to modulate appetite and energy homeostasis

Human GPR17L, hGPR17S, and mGPR17 were expressed in HEK293 cells, and cAMP signaling modulation was measured following treatment with indicated concentrations of MDL29,951 and cAMP stimulation with forskolin (Figure S3 and Table S1)

In January 2025, Novo Nordisk disclosed key findings from the STEP UP study , a Phase IIIb trial within the global STEP program

Warnings & Precautions Your safety matters to us

Why this matters: Daily oral semaglutide offers an alternative to weekly injections Lower cash prices compared to injectables: $149$299/month Available at 70,000+ pharmacies (CVS, Costco) and telehealth platforms like Ro, LifeMD, Weight Watchers, GoodRx, and NovoCare Approved not only for weight loss, but also for reducing cardiovascular risk in adults with obesity Clinical impact: Phase 3 trials showed up to 16.6% average weight loss at 64 weeks Same active ingredient as injectable Wegovy, targeting appetite via GLP-1 pathways Industry perspective: With the global GLP-1 market projected to approach $100B by the 2030s, oral therapies may capture nearly 24% of the market, reshaping access, adherence, and affordability

Based on the profile of participants enrolled in retatrutide trials to date, the drug appears most relevant to adults living with obesity (BMI 30 kg/m) or those who are overweight (BMI 27 kg/m) with weight-related health conditions such as type 2 diabetes, hypertension, dyslipidaemia, or obstructive sleep apnoea